Nordicus Partners Corporation Announces Uplisting to The Nasdaq Capital Market

Nordicus Partners Corporation (NORD), a biotech company focused on developing therapeutics for oral disorders, has received approval for its shares to be listed on The Nasdaq Capital Market. Trading is expected to begin at the open of business on October 30, 2026. Shareholders are not required to take any action as a result of the uplisting.